News

PipelineReview.com3h
Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149
GENEVA, Switzerland I April 17, 2025 I Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of ...
PipelineReview.com18h
Sabin Begins Marburg Vaccine Trial in U.S.
WASHINGTON, DC, USA I April 16, 2025 I The Sabin Vaccine Institute has launched a multi-site Phase 2 clinical trial in the U.S. for its Marburg vaccine ...
PipelineReview.com23h
Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild ...
PipelineReview.com23h
Radiance Announces First Patient Dosing in Phase 1 Clinical Trial of its Next Generation ROR-1 Targeted ADC for Hematologic and Solid Malignancies
BOSTON, MA, USA I April 15, 2025 I Radiance Biopharma, Inc. (“Radiance” or the “Company”), a clinical stage biopharmaceutical company advancing Antibody Drug ...
PipelineReview.com23h
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
MELBOURNE, Australia and INDIANAPOLIS, IN, USA I April 16, 2025 I Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces ...